Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients

Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

NCT00093002 ·Status: COMPLETED ·Phase: PHASE2

ICI 182780 in Treating Women With Metastatic Breast Cancer

NCT00012025 ·Status: COMPLETED ·Phase: PHASE2

Fulvestrant in Metastatic Breast Cancer

NCT03591549 ·Status: UNKNOWN ·Phase: PHASE4

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

NCT01942135 ·Status: COMPLETED ·Phase: PHASE3

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

NCT01797120 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

NCT03202862 ·Status: UNKNOWN ·Phase: PHASE2

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

NCT00234403 ·Status: COMPLETED ·Phase: PHASE2

SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer

NCT00272740 ·Status: COMPLETED ·Phase: PHASE2

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

NCT00570921 ·Status: COMPLETED ·Phase: PHASE2

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

NCT02216786 ·Status: COMPLETED ·Phase: PHASE2

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

NCT00138125 ·Status: TERMINATED ·Phase: PHASE2

Pilot Study of 18F Fluoropaclitaxel (FPAC)

NCT00572598 ·Status: COMPLETED ·Phase: EARLY_PHASE1

ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer

NCT00010153 ·Status: TERMINATED ·Phase: PHASE3

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

NCT00129389 ·Status: COMPLETED ·Phase: PHASE3

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

NCT04920708 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of AFP464 +/- Faslodex in ER + Breast Cancer

NCT01233947 ·Status: TERMINATED ·Phase: PHASE2

Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment

NCT01320111 ·Status: COMPLETED ·Phase: PHASE2

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00020332 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer

NCT01006785 ·Status: TERMINATED ·Phase: PHASE2

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

NCT00752986 ·Status: TERMINATED ·Phase: PHASE2

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

NCT02340221 ·Status: TERMINATED ·Phase: PHASE3

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

NCT00432172 ·Status: COMPLETED ·Phase: PHASE2

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

NCT03377101 ·Status: WITHDRAWN ·Phase: PHASE2

Phase I Study of the Combination of MLN9708 and Fulvestrant

NCT02384746 ·Status: TERMINATED ·Phase: PHASE1